C88.40 — Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission
Is C88.40 billable?
Yes — C88.40 is billable for FY2027. C88.40 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. C88.40 may be submitted for encounters from October 1, 2026 through September 30, 2027.
C88.40 at a glance
| Code | C88.40 |
|---|---|
| Description | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
Which MS-DRGs does C88.40 group to?
C88.40 sits in MDC 17 and helps define the logic of 3 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 820Lymphoma and Leukemia with Major O.R. Procedures with MCCsurgical
- 821Lymphoma and Leukemia with Major O.R. Procedures with CCsurgical
- 822Lymphoma and Leukemia with Major O.R. Procedures without CC/MCCsurgical
As a secondary diagnosis, C88.40 is a complication or comorbidity (CC), which can move a stay into a higher-paying DRG.
How is C88.40 listed in the Alphabetic Index?
The Alphabetic Index lists these routes under C88.4, the nearest indexed parent of C88.40. Use them to find the family, then select the specific code.
- Lymphoma › BALT (of) (malignant)
- Lymphoma › bronchial-associated lymphoid tissue [BALT-lymphoma] (of) (malignant)
- Lymphoma › extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] (of) (malignant)
- Lymphoma › MALT (of) (malignant)
- Lymphoma › mucosa-associated lymphoid tissue [MALT-lymphoma] (of) (malignant)
- Lymphoma › SALT (of) (malignant)
- Lymphoma › skin-associated lymphoid tissue [SALT-lymphoma] (of) (malignant)
Inclusion terms
Alternative wording in documentation that is classified to C88.40.
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] NOS
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] with failed remission
- Lymphoma of bronchial-associated lymphoid tissue [BALT-lymphoma] NOS
- Lymphoma of bronchial-associated lymphoid tissue [BALT-lymphoma] not having achieved remission
- Lymphoma of bronchial-associated lymphoid tissue [BALT-lymphoma] with failed remission
- Lymphoma of skin-associated lymphoid tissue [SALT-lymphoma] NOS
- Lymphoma of skin-associated lymphoid tissue [SALT-lymphoma] not having achieved remission
- Lymphoma of skin-associated lymphoid tissue [SALT-lymphoma] with failed remission
Excludes1 — never code together — inherited from C88
The conditions below can never be reported together with C88.40 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
Excludes1 — never code together — inherited from C88.4
The conditions below can never be reported together with C88.40 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
- high malignant (diffuse large B-cell) lymphoma (C83.3-)
Excludes2 — not included here — inherited from C81-C96
The conditions below are not part of C88.40, but a patient may have both at the same time. When documentation supports it, C88.40 and the excluded code may both be reported.
How long has C88.40 existed?
C88.40 first appears in FY2025.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.